Q2 FY2026 · ended Jun 30, 2026 · Revenue $34,463, -59.2% YoY · Filed Aug 19, 2026
Nutra Pharma Corp. (NPHC) files with the SEC under industry code 2833, Medicinal Chemicals & Botanical Products. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $34,463 and a net loss of $3.9 million. As of Jun 30, 2026 it held $17,600 in cash and investments and $12.6 million in total debt.
Revenue
$34,463
-59.2% vs year-ago quarter
Net income
$-3.95M
-1168.5% vs year-ago quarter
Operating cash flow
$-251,223
+12.9% vs year-ago quarter
Free cash flow
$-219,818
+20.6% vs prior quarter
EPS
$0.00
Dividend per share
None
Shares outstanding
7.16B
+0.0% vs year-ago quarter
Net cash
$-12.56M
Q2 FY2026
Operating margin
-1017.8%
TTM
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- NPHC (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Boca Raton, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1119643
- Former names
- CYBER VITAMIN COM (until Feb 28, 2002)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $34,463 | $27,246 | $28,864 | $70,242 | $84,532 |
| Operating income | -$435,464 | -$379,249 | -$465,914 | -$356,076 | -$290,529 |
| Net income | -$3.9M | -$459,675 | -$488,526 | -$523,520 | $369,577 |
| Diluted EPS | $0.00 | $0.00 | -$0.00 | $0.00 | $0.00 |
| Operating cash flow | -$251,223 | -$327,791 | -$219,818 | -$250,770 | -$288,370 |
| Free cash flow | — | — | -$219,818 | -$276,822 | -$288,370 |
| Total assets | $622,863 | $616,518 | $622,601 | $709,853 | $859,068 |
| Total liabilities | $21.8M | $17.9M | $17.4M | $17.1M | $16.7M |
| Stockholders' equity | -$21.2M | -$17.3M | -$16.8M | -$16.4M | -$15.8M |
| Cash and investments | $17,600 | $39,444 | $29,781 | $21,203 | $96,669 |
| Total debt | $12.6M | $10.0M | $9.8M | $9.7M | $9.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Change in control
|
Sep 2, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 19, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 29, 2026 | Mar 31, 2026 |
| 10-K | Annual report | May 20, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Apr 6, 2026 | Sep 30, 2025 |
| 10-Q | Quarterly report | Mar 25, 2026 | Jun 30, 2025 |
All 349 Nutra Pharma Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.